Malignant disease in the elderly: The aging cancer patient;Bösartige erkrankungen im alter

Internist

Volumn 43, Issue 8, 2002, Pages 959-964

  Kolb, G F ^a  

^a ST BONIFATIUS HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; MITOXANTRONE;

AGING; CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; HUMAN; PATIENT EDUCATION; REVIEW; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; GERIATRIC ASSESSMENT; GERMANY; HUMANS; MIDDLE AGED; NEOPLASMS; PALLIATIVE CARE; PATIENT CARE TEAM; POPULATION DYNAMICS;

EID: 0036705421     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-002-0619-4     Document Type: Review

References (52)

1. Austoker J (1994) Screening for colorectal cancer. BMJ 309: 382-386
2. Balducci L (2000) Geriatric oncology: Challenges for the new century. Eur J Cancer 36: 1741-1754
3. Balducci L (2000) The assessment of the older cancer patient. Schwerpunktheft Geriatische Onkologie. Eur J Ger 4: 168-172
4. Bailes JS (1997) Health care economics of cancer in the elderly. Cancer 80: 1348-1350
5. Bloomfield DJ (1998) Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers: An evidence-based review. J Clin Oncol 16: 1218-1225
6. Bokemeyer C, Lipp HP, Mayer F, Kanz L (1998) Supportive Maßnahmen bei der Chemotherapie älterer Patienten. Arzneimitteltherapie 16: 140-146
7. Cascinu S, Del Ferro E, Catalano E (1996) Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. Am J Clin Oncol 19: 371-374
8. Chatta GS, Price T, Allen RC (1994) Effects of in vivo recombinant methionyl human granuIocyte colony-stimulating factor on the neutrophil response and peripheral blood colonyforming cells in healthy young and elderly adult volunteers. Blood 84: 2923-2929
9. Cohen HJ (1997) The oncology geriatric education retreat. Commentary and conclusions. Cancer 80: 1354-1356
10. Collins C, Weiden PL (1987) Cardiotoxicity of 5-fluorouracil. Cancer Treat Rep 71: 733-736
11. Conti JA, Christman K (1995) Cancer chemotherapy in the elderly. J Clin Gastroenterol 21: 65-71
12. Crespi M, Lisi D (2002) Is colorectal cancer screening by fecal occult blood feasible? Ann Oncol 13: 47-50
13. Dodd MJ, Onishi K, Dibble SL, Larson PJ (1996) Differences in nausea, vomiting and retching between younger and older outpatients receiving cancerchemotherapy. Cancer Nursing 19: 155-161
14. Dunn CJ, Goa KL (1996) Mitoxantrone: A review of its pharmacological properties and use in nonlymphoblastic leukemia. Drugs Aging 9: 122-147
15. Eriksson KM, Cederholm T, Palmblad JEW (1998) Nutrition and acute leukemia in adults. Relation between nutritional status and infectious complications during remission induction. Cancer 82: 1071-1077
16. Extermann M, Balducci L, Lyman GH (2000) What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 18: 1709-1717
17. Extermann M (1997) Acute leukemia in the older patient. Clin Geriatr Med 13: 227-244
18. Friedrich C, Pientka L, Bokemeyer C, Kolb G (2002) Assessment bei geriatrisch-onkologischen Patienten. Onkologie (in Vorbereitung)
19. Gallo JJ, Stanley L, Zack AE, Reichel W (1995) Multidimensional assessment of the older patient. In: Reichel W (ed) Care of the Elderly. William & Wilkins, Baltimore, pp 15-30
20. Giovanazzi-Bannon S, Rademaker A, Lai G, Benson AB (1994) Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: An Illinois Cancer Center study. J Clin Oncol 12: 2447-2452
21. Goodwin JS, Hunt WC, Samet JM (1991) A population-based study of functional status and social support of elderly patients newly diagnosed with cancer. Arch Intern Med 151: 366-370
22. Gottlieb D, Bradstock K, Koutts J (1987) The neurotoxicity of high-dose cytosin arabinosid is age related. Cancer 60: 1439-1441
23. Grilli R, Minozzi S, Tinazzi A, Labianca R, Sheldon TA, Liberati A (1998) Do specialists do it better? The impact of specialization on the processes and outcomes of care for cancer patients. Ann Oncol 9: 365-375
24. Hamermann D (1999) Towards an understanding of frailty. Ann Intern Med 130: 945-950
25. Henderson IC, Allegra JC, Woodcock T (1989) Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560-571
26. Hiddemann W, Kern W, Wörmann B, Büchner T (1998) Acute Myeloid Leukemia in Elderly Patients. ASCO Educational Book
27. Honecker F, Wedding U, Kolb G, Bokemeyer C (2001) Chemotherapie des kolorektalen Karzinoms - Welche Therapie ist bei älteren Patienten gerechtfertigt? Onkologie 24: 87-94
28. Hutchins LF, Unger JM, Crowley JJ, Coltmann CA, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341: 2061-2067
29. Jackson DV, Wells HB, Atkins JN (1988) Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med 84: 1016-1022
30. Jorke D (1998) Ethische Dimension der geriatrischen Onkologie. Onkotogie 4: 61-65
31. Kennedy BJ (1997) Aging and cancer. Geriatric oncology - Keynote address to integrating geriatrics into oncology education. Cancer 80: 1270-1272
32. Kleeberg UR (1998) Ergebnisqualität in der internistischen Onkologie. Onkologe 4: 414-419
33. Kolb G (2000) Geriatrische Onkologie als Herausforderung. Euro J Ger 2: 155-162
34. Kolb G (1993) Granulozytäre Unverträglichkeitsreaktionen unter der Hämodialysebehandlung. Fortschr Med 111: 130-131
35. Kolb G, Nolting C, Eckle I, Müller T, Lange H, Havemann K (1991) The role of membrane contact in hemodialysis induced granulocyte activation. Nephron 57: 64-68
36. Kolb G (1996) Pulmonale (Neben)Wirkungen extrakorporaler Therapieverfahten. Wien Kiln Wochschr 108: 15-20
37. Kronborg O, Fenger C, Olsen J, Dan Jorgensen O, Sondergaard O (1996) Randomised study of screening for colorectal cancer with fecaloccult-blood test. Lancet 348: 1467-1471
38. Lipp HP, Bokemeyer C (2000) Supportivtherapie in der klinischen Onkologie. Krankenhauspharmazie 21: 559-575
39. Lipschitz DA, Udupa KB (1986) Age and the hematopoetic system. J Am Geriatr Soc 34: 448-454
40. Lipschitz DA (1995) Age related decline in hematopetic reserve capacity. Semin Oncol 22 (Suppl 1): 3-6
41. Manus B, Braglmann R, Ambrecht U, Stolte M, Sockbrugger RW (1996) Screening for gastrointestinal neoplasia: Efficacy and cost of two different approaches in a clinical rehabilitation centre. Eur J Cancer Prev 5: 49-55
42. Morgan R, Spencer B, King D (1998) Rectal examinations in the elderly: Attitudes of patients and doctors. Age Ageing 27: 353-356
43. Mosseri M, Fingertr HJ, Varticovski L (1993) In vitro evidence that myocardial ischemia resulting from 5-fluorouracilchemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 53: 3028-3033
44. Olson RD, Mushlin PS (1990) Doxorubicin cardiotoxicity: Analysis of prevailing hypothesis. FASEB J 4: 3076-3084
45. Opalka B (1998) Immuntherapie von Tumorerkrankungen - Probleme und neuere klinische Ergebnisse. Tumordiagnose Ther 19: 12-16
46. Pouillart P, Follezou JY, Palangie T (1994) Long-term results of a randomised trial comparing regimens of cyclophospamide and fluorouracil with either mitoxantrone or doxorubicin in patients with advanced breast cancer. Eur J Cancer 30A: 715-716
47. Reuben DB (1997) Geriatric assessment in oncology. Cancer 80: 1311-1316
48. Rothstein G (1993) Hematopoiesis in the aged: A model of hematopoeitic dysregulation? Blood 82: 2601-2604
49. Rowe JM, Andersen JW, Mazza JJ (1995) A randomized, placebo controlled phase III study of granulocyte-macrophage-colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 86: 457-462
50. Rowe JM, Liesveld JL (1999) Hematopoietic growth factors in acute leukemia. Leukemia 11: 328-341
51. Wenisch C, Patruta S, Daxböck F, Krause R, Hörl W (2000) Effect of age on human neutrophil function. J Leuk Biol 67: 40-41
52. Wilsede Schule für Onkologie und Hämatologie (2001) 33. Seminar der Wilsede Schule 21.03.-24.03.2001.Teil I: Geriatrische Onkologie. Reader erhältlich über Prof. Dr. Illiger, Klinik für Innere Medizin II, Städt. Kliniken Oldenburg, Dr. Eden-Straße 10,26133 Oldenburg